• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

FDA Approves Darzalex Faspro Regimen for Some With Multiple Myeloma

by | Jul 30, 2024 | Uncategorized

Source: CureToday articles The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for select patients newly diagnosed with multiple myeloma. Read More

Myeloma-Related Questions to Ask After Diagnosis

by | Jul 29, 2024 | Uncategorized

Source: CureToday articles From finding reputable info to asking, “Do I really need all these drugs?” experts weighed in on important questions to ask after a myeloma diagnosis. Read More

What I’m Glad I Knew (and Didn’t) With Myeloma

by | Jul 27, 2024 | Uncategorized

Source: CureToday articles When I fell in love, I didn’t know my husband would end up getting cancer, but I also glad I learned that normal people like me can make a difference. Read More

Isa-KRd Elicits Responses in Some With Newly Diagnosed Multiple Myeloma

by | Jul 25, 2024 | Uncategorized

Source: CureToday articles “Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Read More

My Decision to Receive CAR-T Cell Therapy for Multiple Myeloma

by | Jul 20, 2024 | Uncategorized

Source: CureToday articles I decided to receive CAR-T cell therapy for multiple myeloma when my previous regimen stopped working and now, I’m living my best life. Read More

Finding Support After a Myeloma Diagnosis

by | Jul 12, 2024 | Uncategorized

Source: CureToday articles I was diagnosed with myeloma more than two decades ago and am lucky to have support throughout. Read More
« Older Entries
Next Entries »

Recent Content

  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
  • VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
  • Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
  • Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
  • Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT